Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Issuer: Mainz BioMed N.V. / Key word(s): Conference Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) 10.11.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

BERKELEY, US and MAINZ, Germany – November 10, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, 2025, in Bad Kreuznach, Germany.

The annual GARPS conference brings together clinical and scientific expertise from across the Rhineland-Palatinate region, serving as an important platform for knowledge exchange in the fields of gastroenterology and hepatology. This form of regional congress promotes valuable dialogue between universities, hospitals, private practices, and representatives of the research and diagnostics industry.

Mainz Biomed will use the opportunity to further strengthen relationships with key opinion leaders in gastroenterology, exchange insights on the future of cancer prevention, and present its current flagship product, ColoAlert, and further upcoming diagnostic solutions designed to enhance early detection of colorectal and other cancers.

Attendees are invited to visit the booth to learn more about the critical significance of early colorectal cancer detection and to explore potential collaborations with physicians and how to offer ColoAlert to their patients.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.